Detalhe da pesquisa
1.
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet
; 401(10388): 1571-1583, 2023 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37116523
2.
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
Blood
; 139(23): 3366-3375, 2022 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35081255
3.
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia.
Haematologica
; 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38634143
4.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real-world data from eight US academic centers.
Am J Hematol
; 99(4): 606-614, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38342997
5.
Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia.
Am J Hematol
; 98(8): 1254-1264, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37334852
6.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
N Engl J Med
; 381(18): 1728-1740, 2019 10 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-31665578
7.
Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study.
Haematologica
; 107(4): 836-843, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34348451
8.
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors.
Am J Hematol
; 97(3): 322-328, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981560
9.
Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.
J Oncol Pharm Pract
; 28(4): 892-897, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-35191732
10.
Availability of FLT3 inhibitors: how do we use them?
Blood
; 134(9): 741-745, 2019 08 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-31243041
11.
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.
Blood
; 132(6): 598-607, 2018 08 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29875101
12.
Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia: results from an international collaborative study.
Haematologica
; 105(1): 161-169, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31004014
13.
Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents.
Am J Hematol
; 95(7): 792-798, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32242967
14.
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 20(7): 984-997, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31175001
15.
Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
Blood
; 129(2): 177-187, 2017 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-27777238
16.
Heterogeneous resistance to quizartinib in acute myeloid leukemia revealed by single-cell analysis.
Blood
; 130(1): 48-58, 2017 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28490572
17.
The most novel of the novel agents for acute myeloid leukemia.
Curr Opin Hematol
; 25(2): 81-89, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29278535
18.
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Lancet Oncol
; 19(7): 889-903, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29859851
19.
Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition.
Invest New Drugs
; 36(4): 657-666, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29607465
20.
The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Am J Hematol
; 98(12): E364-E368, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37815132